Login
ETFMG Treatments Testing and Advancements ETF NYSE Arca: GERM
GERM is designed to give exposure to the biotech companies directly engaged in the testing and treatments of infectious diseases. Focused on advancements with targeted exposure to the forefront of R&D, vaccines, therapies and testing technologies
| Name | ETFMG Treatments Testing and Advancements ETF |
| Ticker | GERM |
| Exchange | NYSE Arca |
| Category | Health Care |
| Sub Category | Diagnostics |
|
Price
52W Low/High |
36.21
24.63 / 44.11 |
| Momentum | Neutral |
| AUM | - |
| 1Y Total Return |
43.99%
Above Average |
| 1Y Volatility |
35.58%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
GERM is designed to give exposure to the biotech companies directly engaged in the testing and treatments of infectious diseases. Focused on advancements with targeted exposure to the forefront of R&D, vaccines, therapies and testing technologies
Details
| Ticker | GERM |
| Name | ETFMG Treatments Testing and Advancements ETF |
| ISIN | US26924G7631 |
| CUSIP | 26924G763 |
| Exchange | NYSE Arca |
| Category | Health Care |
| Sub Category | Diagnostics |
| Country | USA |
| Currency | U.S. Dollar |
| Benchmark | Prime Treatments, Testing and Advancements Index |
Share as of 5/14/21
| Close Price | 36.21 |
| 52W Low/High | 24.63 / 44.11 |
| 1Y Total Return |
43.99%
Above Average |
| 1Y Volatility |
35.58%
High Risk |
| Beta | 0.00 |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dist. Frequency | - |
| Dividend Yield | - |
Data as of 5/16/21
| AUM | - |
| Discount/Premium | - |
| NAV | - |
| Shares Outstanding | - |
| Volume 20D Avg | - |
| Nbr of Holdings | - |
| ETF Global Risk Rank | - |
| Net Expense | - |
| Options Available | - |
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available